Invivo Therapeutics Holdings Corp. (NVIV) SEC Filing 8-K Material Event for the period ending Tuesday, July 2, 2019

SEC Filings

Invivo Therapeutics Holdings Corp.

CIK: 1705402 Ticker: NVIV

View differences made from one to another to evaluate Invivo Therapeutics Holdings Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Invivo Therapeutics Holdings Corp..


Assess how Invivo Therapeutics Holdings Corp.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Invivo Therapeutics Holdings Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: NVIV
CIK: 1292519
Form Type: 8-K Corporate News
Accession Number: 0001558370-19-006018
Submitted to the SEC: Fri Jul 05 2019 8:00:16 AM EST
Accepted by the SEC: Fri Jul 05 2019
Period: Tuesday, July 2, 2019
Industry: Surgical And Medical Instruments And Apparatus
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: